Visible Results

In Trial 6, adolescent patients with moderate‑to‑severe atopic dermatitis not adequately controlled with topical prescription treatments were randomized to DUPIXENT or placebo. Adolescents ≥60 kg received DUPIXENT 300 mg Q2W following a 600 mg loading dose, while adolescents <60 kg received 200 mg Q2W following a 400 mg loading dose. The primary endpoint was the change from baseline to Week 16 in the proportion of subjects with an Investigator's Global Assessment (IGA) of 0 (clear) or 1 (almost clear) and ≥2‑point improvement.1,2

Significant skin clearance was demonstrated in adolescents (primary endpoint; P<0.001)1-3,a

Efficacy Results of DUPIXENT
at Week 16 (FAS)
clear or
clear skin
(IGA 0 or 1)
24% 2%
  • a Responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2‑points on a 0‑4 scale at Week 16 (primary efficacy outcome).

Visible Results in an Adolescent Patient

Adolescent patient achieved a 2-point improvement in IGA


IGA 4 (severe)

Week 16:

IGA 2 (mild)

Actual 12-year-old patient in the phase 3 adolescent DUPIXENT trial. Patient had a baseline IGA of 4 and EASI of 31. Individual results may vary.

A clinical responder was defined as a patient achieving IGA 0 or 1 and at least a 2-point
improvement from baseline1

  • This adolescent patient would not have met the primary endpoint in the clinical trials based on their IGA scores at Week 16
See Changes in Adults Not Achieving
IGA 0 or 1
  • BSA, body surface area.
Dosing and Administration Thinking about prescribing
DUPIXENT? Find the information you
need to get started.
Start Now
Connect With a Rep Have questions about DUPIXENT? Get
answers from a representative.
Request a Visit
DUPIXENT MyWay Get access support and information
about benefits investigations,
prior authorizations, and Medical
Necessity and appeal letters.
Explore Access Resources
  1. DUPIXENT Prescribing Information.
  2. Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial [published online November 6, 2019]. JAMA Dermatol. doi: 10.1001/jamadermatol.2019.3336
  3. Data on file, Regeneron Pharmaceuticals, Inc.